nonalcoholic fatty liver disease emerging threat obese diabetic individuals abstract nonalcoholic fatty liver disease nafld common liver disease western world incidence increasing rapidly nafld spectrum ranging simple steatosis benign hepatically nonalcoholic steatohepatitis nash progress cirrhosis obesity insulin resistance type num diabetes mellitus dyslipidemia important risk factors nafld due heavy enrichment metabolic risk factors individuals nafld significantly higher risk cardiovascular disease individuals nafld higher incidence type num diabetes diagnosis nafld requires imaging evidence hepatic steatosis absence competing etiologies including significant alcohol consumption liver biopsy remains gold standard diagnosing nash determining prognosis weight loss remains cornerstone treatment weight loss num believed improve steatosis num weight loss improve steatohepatitis number pharmacologic therapies investigated treat nash agents vitamin thiazolidinediones shown promise select patient subgroups 
